Currently, tyrosine kinase (TK) inhibitors are available in the market as first line of drugs such as gefitinib and erlotinib to treat non-small-cell lung cancer (NSCLC), but the tumors are going to be resistant against these drugs due to secondary mutation in T790M. This evidence concerns the gene TKT and non-small cell lung carcinoma.